Clinical trials: Allogeneic Disease
T1DM - Type 1 Diabetes Mellitus
Allogeneic Anti-CD7 CAR-T for Type 1 Diabetes
Type 1 diabetes mellitus (T1DM) is a T cell-mediated autoimmune disease characterized by autoimmune destruction of pancreatic beta cells, leading to absolute insulin deficiency and lifelong dependence on exogenous insulin.
- Trial name
- NCT07528105
- Testing
- Allogeneic CD7-Targeted CAR-T Cell Injection
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai Zhongshan Hospital
Lymphoma
Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma
Primary Objectives: 1. To evaluate the role of autologous and allogenic stem cell transplantation with Campath-1H for patients with peripheral T-cell lymphoma (PTCL). 2.
- Trial name
- NCT00505921
- Testing
- Campath-1H, G-CSF, GM-CSF
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- M.D. Anderson Cancer Center
Primary Immunodeficiencies, Inborn Errors of Metabolism
Treosulfan-based Versus Busulfan-based Conditioning in Paediatric Patients With Non-malignant Diseases
The aim of the trial is to describe the safety and efficacy of intravenous (i.v.) Treosulfan compared to the conventional (myeloablative) dose of i.v.
- Conditions
- Primary Immunodeficiencies, Inborn Errors of Metabolism, Haemoglobinopathies, Bone Marrow Failure Syndromes
- Trial name
- NCT02349906
- Testing
- Treosulfan, Busilvex
- Where
- 21 sites in Czechia, Germany and 2 more
- Volunteers
- 106 people
- Sponsor
- medac GmbH
Severe Congenital Neutropenia, GATA2 Deficiency
Total Lymphoid Irradiation Pre-HSCT in Severe Congenital Neutropenia
Severe congenital neutropenia (SCN) is a group of primary immunodeficiencies caused by distinct gene mutations and characterized by neutrophil maturation impairment, which leads to neutropenia, predisposition to severe bacterial…
- Trial name
- NCT04844177
- Testing
- conditioning with TLI
- Where
- Russia
- Volunteers
- 10 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Treosulfan-based Conditioning for Transplantation in AML/MDS
The study hypotheses is that the introduction of dose escalated treosulfan, in substitution to busulfan, will reduce toxicity after allogeneic transplantation while improving myeloablation and and disease control in patients with…
- Trial name
- NCT00491634
- Testing
- treosulfan
- Where
- Israel
- Volunteers
- 24 people
- Sponsor
- Dr. Avichai Shimoni MD
Lung Cancer
Vaccine Therapy in Patients With Stages IIIB/IV Non-Small Cell Lung Cancer Who Have Finished First-Line Chemotherapy
RATIONALE: Vaccines made from gene-modified tumor cells may help the body build an immune response to kill tumor cells. PURPOSE: This randomized phase I/II trial is studying the side effects of vaccine therapy and to see how well…
- Trial name
- NCT00534209
- Testing
- Allogeneic B7.1/HLA-A1
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- University of Miami
Myelofibrosis
Survival in Myelofibrosis Patients After Allogeneic Hematopoietic Stem Cell Transplantation in Five Centers in France
The investigators would like to conduct a retrospective study in five centers in France in the goal to evaluate the survival of patients receiving allogeneic hematopoietic stem cell transplantation for myelofibrosis.
- Trial name
- SYMFASCT (NCT04282421)
- Volunteers
- 58 people
- Sponsor
- Central Hospital, Nancy, France
Acute Myeloid Leukemia
A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia
WiNK is a Phase I/IIa trial to evaluate the safety and efficacy of oNKord® in 33 adults with acute myeloid leukemia (AML) who are in morphologic complete remission with residual measurable disease and who are currently not…
- Trial name
- NCT04632316
- Testing
- Cyclophosphamide-Fludarabine (Cy/Flu), oNKord®
- Where
- 10 sites in Belgium, France and 3 more
- Volunteers
- 33 people
- Sponsor
- Glycostem Therapeutics BV
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
The purpose of this study is to determine if hyperbaric oxygen therapy is safe in the setting of stem cell transplantation. This study will also determine if hyperbaric oxygen therapy improves engraftment, graft versus host…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Atypical Chronic Myeloid Leukemia
- Trial name
- NCT03964506
- Testing
- Hyperbaric oxygen
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Omar Aljitawi
Anemia of Prematurity
Autologous Cord Blood Transfusion in Preterm Infants
The purpose of this study is to investigate the efficacy and safety of autologous cord blood transfusions in very-low-birth-weight premature infants, and to evaluate the developmental outcomes of the infants who received…
- Trial name
- NCT02101086
- Testing
- Blood transfusion
- Where
- Turkey (Türkiye)
- Volunteers
- 39 people
- Sponsor
- Ankara University
Infantile Spinal Muscular Atrophy, Type I [Werdnig- Hoffman]
Allogeneic Adipose Derived Stem Cells for Werdnig Hoffman Patients
Spinal Muscular Atrophy (SMA) is an autosomal recessive disease of motor neurons. In the early 1980s, Werdnig from Vienna University and Hoffman from Heidelberg University described this disorder.
- Trial name
- NCT02855112
- Testing
- Adipose derived mesenchymal stem cell
- Where
- Iran
- Volunteers
- 10 people
- Sponsor
- Tehran University of Medical Sciences
Respiratory Distress Syndrome, Adult, Bronchiolitis Obliterans
Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation
The purpose of this study is to determine the effects of etanercept, and define the toxicity, when administered to patients with acute non-infectious lung injury (idiopathic pneumonia syndrome, IPS) and with subacute pulmonary…
- Conditions
- Respiratory Distress Syndrome, Adult, Bronchiolitis Obliterans, Pneumonia
- Trial name
- NCT00029328
- Testing
- etanercept
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- FDA Office of Orphan Products Development
Systemic Lupus Erythematosus, Lupus Nephritis
CHT105 for the Treatment of Refractory Lupus Nephritis
Systemic lupus erythematosus (SLE) is the most common systemic autoimmune disease in China. The kidneys are the organ most frequently affected in SLE and a major cause of mortality among SLE patients.
- Trial name
- NCT07517536
- Testing
- anti-CD19/70 CAR T cells (CHT105)
- Where
- China
- Volunteers
- 14 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Leukemia
PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute Leukaemia
This pilot study was designed in order to evaluate the safety and efficacy of an AmBisome loading dose regimen, in a weekly administration schedule, during the aplastic phase following induction or consolidation chemotherapy for…
- Trial name
- NCT00362544
- Testing
- Ambisome
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Gilead Sciences
Acute Myeloid Leukaemia (AML), Myelodysplastic Syndromes (MDS)
Panobinostat Maintenance After HSCT fo High-risk AML and MDS
Aim of this prospective randomized trial is to compare maintenance treatment with panobinostat interspersed with donor lymphocyte infusions (DLI) versus the standard approach of pre-emptive DLI alone in patients with poor-risk…
- Trial name
- NCT04326764
- Testing
- Panobinostat
- Where
- 19 sites in Germany, Netherlands
- Volunteers
- 52 people
- Sponsor
- Goethe University
Graft vs Host Disease
Prevention of the Graft-Versus-Host-Disease in Patients After Stem Cell Transplantation With Tacrolimus and Everolimus
The purpose of this pilot study is to provide preliminary data about the efficacy and the safety of the combination of tacrolimus with everolimus in the prophylaxis of the graft-versus-host-disease (GvHD) in patients after…
- Trial name
- NCT00117702
- Testing
- Tacrolimus, Everolimus
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Technische Universität Dresden
Allogeneic Transplantation (Non T-cell Depleted)
Phase I Clinical Trial to Assess Safety of UV Phototherapy for the Prevention of GVHD Post Allogeneic SCT
The primary goal of thos study is to assess safety of Ultraviolet (UV) Phototherapy for the Prevention of Graft versus Host Disease after allogeneic stem cell transplantation (Phase I - Clinical trial).
- Trial name
- NCT00524953
- Testing
- EUMATRON - EN 600 NT
- Where
- Israel
- Sponsor
- Hadassah Medical Organization
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Cytomegalovirus
Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT
This trial studies the side effects and how well allogeneic cytomegalovirus-specific cytotoxic T lymphocytes (donor cytomegalovirus [CMV] specific cytotoxic T-lymphocytes [CTLs]) or allogeneic adenovirus-specific cytotoxic T…
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Cytomegalovirus, Donor, Solid Organ Transplantation Recipient
- Trial name
- NCT03665675
- Testing
- Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes, Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sumithira Vasu
Multiple Myeloma and Plasma Cell Neoplasm
Biological Therapy in Treating Patients With Multiple Myeloma That Has Recurred Following Bone Marrow Transplantation
RATIONALE: White blood cells from donors may be able to kill cancer cells in patients with multiple myeloma that has recurred following bone marrow transplantation.
- Trial name
- NCT00003153
- Testing
- therapeutic allogeneic lymphocytes
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Eastern Cooperative Oncology Group
Acute Lymphoblastic Leukemia, ALL
Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD
Patients are being asked to participate in this study because treatment for their disease requires a stem cell transplant (SCT).
- Conditions
- Acute Lymphoblastic Leukemia, ALL, Acute Myelogenous Leukemia, AML
- Trial name
- IL2 for GVHD (NCT00539695)
- Testing
- IL-2
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Baylor College of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.